1. Phase 1b results from OP-1250-001, a dose escalation and dose expansion study of OP-1250, an oral CERAN, in subjects with advanced and/or metastatic estrogen receptor (ER)-positive, HER2-negative breast cancer (NCT04505826). (October 2022) Authors: Hamilton, E.; Meisel, J.; Alemany, C.; Virginia, B.; Lin, N.; Wesolowski, R.; Mathauda-Sahota, G.; Makower, D.; Lawrence, J.; Faltaos, D.; Mitri, Z.; Sabanathan, D.; Clark, D.; Pluard, T.; Hui, R.; McCarthy, N.; Patel, M. Journal: European journal of cancer Issue: Volume 174(2022)Supplement 1 Page Start: S36 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗